National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:National Institute of Neurological Disorders and Stroke - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014347
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, brain tumors, developmental disorders stroke, epilepsy, Parkinson’s disease, traumatic brain injury, stem cell research, health disparities research, bioengineering research and autism, among others. Its activities comprise training of investigators in basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders. NINDS’ serves scientists, clinicians, and the public. The Institute collaborates with other NIH components, federal agencies, and with voluntary professional and commercial organizations. NINDS is headquartered in Bethesda, Maryland, the US.

National Institute of Neurological Disorders and Stroke – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 11
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 12
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 13
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 14
Licensing Agreements 15
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 15
National Institute of Neurological Disorders and Stroke – Key Competitors 16
National Institute of Neurological Disorders and Stroke – Key Employees 17
National Institute of Neurological Disorders and Stroke – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Nov 06, 2017: The Wistar Institute Awarded More Than $16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 19
Oct 31, 2017: NIH: Study shows how memories ripple through the brain 21
Oct 26, 2017: Scientists find a role for Parkinson’s gene in the brain 22
Oct 23, 2017: Penn Radiology Researcher Awarded $3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 23
Oct 18, 2017: New insight into how brain cells die in Alzheimer’s disease and FTD 24
Oct 02, 2017: CU Researchers win prestigious $2 million NIH grant for brain study 26
Sep 20, 2017: Immune cells may heal bleeding brain after strokes 27
Sep 07, 2017: NIH awards nearly $100 million for Autism Centers of Excellence program 29
Aug 18, 2017: Nortis Awarded $688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrier 31
Aug 15, 2017: New $1.9M federal grant to fund JAX studies of microbiome’s role in multiple sclerosis 32
Jul 06, 2017: NIH and Collaborators Identify the Genomic Cause for Carey-Fineman-Ziter Syndrome 33
Jun 21, 2017: Researchers uncover genetic gains and losses in Tourette syndrome 35
Jun 20, 2017: BlackThorn Therapeutics to Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor Antagonist Program 36
Jan 26, 2017: NIH initiates pilot grant program for innovative neurological research 37
Dec 01, 2016: Castro Announces $5.29M for UTSA Brain Health Research 41
Oct 13, 2016: Recombinetics Awarded Two NIH Grants to Develop Humanized Swine Models of Alzheimer’s Disease and Neurofibromatosis 2 42
Oct 07, 2016: Researchers find novel function for old protein in work that could lead to new ways to protect brain from stroke damage 43
Aug 10, 2016: NIH-funded study supports surgery as treatment for myasthenia gravis 44
Apr 07, 2016: Publication highlights release of muscular dystrophy action plan 46
Mar 07, 2016: Eye cells may use math to detect motion 47
Feb 18, 2016: Surgery and stenting safe, effective lowering long-term risk of stroke 48
Feb 18, 2016: NIH-supported trials test hormonal therapy in older men with low testosterone levels 49
Feb 15, 2016: Mind-Controlled Prosthetic Arm Moves Individual ‘Fingers’ 50
Product News 52
Jun 24, 2016: Manufactured stem cells to advance clinical research 52
Other Significant Developments 53
Feb 04, 2016: New members selected for National Advisory Neurological Disorders and Stroke Council 53
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Key Facts 2
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Institute of Neurological Disorders and Stroke, Deals By Therapy Area, 2011 to YTD 2017 9
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 11
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 12
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 13
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 14
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 15
National Institute of Neurological Disorders and Stroke, Key Competitors 16
National Institute of Neurological Disorders and Stroke, Key Employees 17

★海外企業調査レポート[National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (874):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Guangzhou Baiyunshan Pharmaceutical) is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers herbal tea, Chinese and Western medicine, intermed …
  • PT PLN (Persero):企業の戦略的SWOT分析
    PT PLN (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Samba Private Banking:企業の戦略・SWOT・財務情報
    Samba Private Banking - Strategy, SWOT and Corporate Finance Report Summary Samba Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Arcadis NV:戦略・SWOT・企業財務分析
    Arcadis NV - Strategy, SWOT and Corporate Finance Report Summary Arcadis NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Airbus SE.:企業の戦略・SWOT・財務分析
    Airbus SE. - Strategy, SWOT and Corporate Finance Report Summary Airbus SE. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • All in West! Capital Corporation:戦略・SWOT・企業財務分析
    All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • JAMCO Corporation:企業の戦略・SWOT・財務情報
    JAMCO Corporation - Strategy, SWOT and Corporate Finance Report Summary JAMCO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • KSK Energy Ventures Ltd (KSK):企業の財務・戦略的SWOT分析
    KSK Energy Ventures Ltd (KSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Panoro Energy ASA (PEN):企業の財務・戦略的SWOT分析
    Summary Panoro Energy ASA (Panoro) is an independent oil and gas exploration and development company that explores, develops and produces oil and gas properties in Brazil and West Africa. It holds interests in production and exploration assets in Santos and Camamu Almada basins in Brazil. It also ho …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Red Hill Iron Limited:企業の戦略・SWOT・財務分析
    Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report Summary Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • salesforce.com, inc.:企業の戦略・SWOT・財務情報
    salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report Summary salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Secure Energy Services Inc (SES):石油・ガス:M&Aディール及び事業提携情報
    Summary Secure Energy Services Inc. (Secure Energy) is an energy services company. It provides specialized services to upstream oil and natural gas companies operating in the Western Canadian Sedimentary Basin (WCSB) and North Dakota. The company assists these companies with the handling, processing …
  • Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析
    Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Great Eastern Energy Corp Ltd (GEEC):企業の財務・戦略的SWOT分析
    Summary Great Eastern Energy Corp Ltd (GEECL), a subsidiary of YKM Holdings Pvt Ltd, is an oil and gas exploration and production company. The company carries out extraction and sale of coal bed methane coalbed methane gas. It operates upstream, midstream and downstream projects in Raniganj south bl …
  • Arab International Bank:企業の戦略・SWOT・財務分析
    Arab International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Citibank Berhad:企業の戦略的SWOT分析
    Citibank Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Bruce Power L.P.:電力:M&Aディール及び事業提携情報
    Summary Bruce Power L.P. (Bruce Power) is a nuclear power provider. The company is established as a partnership between TransCanada Corporation, Borealis Infrastructure, The Power Workers’ Union and The Society of Energy Professionals. It operates nuclear power facilities utilizing Canada Deuterium …
  • IXICO Plc (IXI):企業の財務・戦略的SWOT分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as Assessa and trial tracker. Assessa provides web-based platform to tra …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆